The U.S. Food and Drug Administration yesterday asked Endo Pharmaceuticals to remove its opioid pain medication Opana ER from the market, citing the potential for the reformulated drug to be abused. “We will continue to take regulatory steps when we see situations where an opioid product’s risks outweigh its benefits, not only for its intended patient population but also in regard to its potential for misuse and abuse,” said FDA Commissioner Scott Gottlieb, M.D.

Related News Articles

Webinar Recordings
Member
Learn how a Patient Risk Assessment Profile allowed nurses to proactively assess patient risk to guide staffing decisions and nurse-patient assignment.…
Webinar Recordings
Member
Tuesday, August 6, 2019
Letter
Public
AHA encourages Congressional leaders to pass the Pandemic and All-Hazards Preparedness…
Issue Brief
How are value and health equity connected?
Letter
Public
Download the letter (PDF) below Re: CMS—3346—P, Medicare
Case Studies
In 2001, a Samaritan Health Services (SHS) physician, Dr. Richard Wopat, recognized the need to improve birth outcomes of high-risk pregnant women in the…